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Abstract
Background: Emerging evidence indicates that reactive microglia-initiated inflammatory responses are responsible
for secondary damage after primary traumatic spinal cord injury (SCI); epidermal growth factor receptor (EGFR)
signaling may be involved in cell activation. In this report, we investigate the influence of EGFR signaling inhibition
on microglia activation, proinflammatory cytokine production, and the neuronal microenvironment after SCI.
Methods: Lipopolysaccharide-treated primary microglia/BV2 line cells and SCI rats were used as model systems.
Both C225 and AG1478 were used to inhibit EGFR signaling activation. Cell activation and EGFR phosphorylation
were observed after fluorescent staining and western blot. Production of interleukin-1beta (IL-1β) and tumor
necrosis factor alpha (TNFα) was tested by reverse transcription PCR and ELISA. Western blot was performed to
semi-quantify the expression of EGFR/phospho-EGFR, and phosphorylation of Erk, JNK and p38 mitogen-activated
protein kinases (MAPK). Wet-dry weight was compared to show tissue edema. Finally, axonal tracing and functional
scoring were performed to show recovery of rats.
Results: EGFR phosphorylation was found to parallel microglia activation, while EGFR blockade inhibited activation-
associated cell morphological changes and production of IL-1β and TNFα. EGFR blockade significantly
downregulated the elevated MAPK activation after cell activation; selective MAPK inhibitors depressed production
of cytokines to a certain degree, suggesting that MAPK mediates the depression of microglia activation brought
about by EGFR inhibitors. Subsequently, seven-day continual infusion of C225 or AG1478 in rats: reduced the
expression of phospho-EGFR, phosphorylation of Erk and p38 MAPK, and production of IL-1β and TNFα; lessened
neuroinflammation-associated secondary damage, like microglia/astrocyte activation, tissue edema and glial scar/
cavity formation; and enhanced axonal outgrowth and functional recovery.
Conclusions: These findings indicate that inhibition of EGFR/MAPK suppresses microglia activation and associated
cytokine production; reduces neuroinflammation-associated secondary damage, thus provides neuroprotection to
SCI rats, suggesting that EGFR may be a therapeutic target, and C225 and AG1478 have potential for use in SCI
treatment.
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Backgrounds
The pathophysiology of traumatic spinal cord injury
(SCI) is thought to include two stages [1]. As primary in-
sult, the direct mechanical damage cannot be therapeut-
ically influenced. However, secondary damage, including
electrolyte abnormalities, free radical formation, vascular
ischemia, edema, posttraumatic inflammatory reaction,
apoptosis and other processes, are amenable to various
therapeutic interventions. In particular, reports empha-
sizing the importance of the inflammatory process in
mediating tissue damage after SCI have been accumu-
lating [2-4]. Although inflammation is a physiological
response to injury, evidence suggests that early inflam-
matory changes after SCI are detrimental, as reviewed
by [5], leading to glial scar formation, neuronal loss
and demyelination, ultimately worsening outcomes.
Microglia are a prominent source of inflammatory
mediators; these cells undergo profound activation in
response to injury (reviewed by [6]). They constantly
survey the microenvironment for noxious agents and
injurious processes, respond to extracellular signals,
clean cellular debris and toxic substances, and secret
trophic factors, thereby providing neuroprotection after
central nervous system (CNS) injury. On the other
hand, activation of microglia, with resultant production
of proinflammatory mediators and neurotoxic mole-
cules, is involved in the spread of secondary injury.
There is mounting evidence that microglia activation is
one of the major causes of secondary damage after SCI,
and that suppressing it can reduce tissue damage and
improve morphological/functional recovery [7-9].
Modulating the microglial inflammatory process might
create a niche environment for tissue repair. Recently, a
well-documented receptor, epidermal growth factor re-
ceptor (EGFR), attracted much attention for its potency
in regulating cell activation. Binding of ligands like EGF
and tumor necrosis factor α (TNFα), the tyrosine-
specific protein kinase intrinsic to EGFR, results in
activation, and is followed by transactivation of mitogen-
activated protein kinase (MAPK) and other downstream
signal pathways [10]. The activation of MAPK has been
reported to be essential for production of several inflam-
matory cytokines, such as interleukin (IL)-1β, TNFα and
IL-6 [11,12]. In the CNS, EGFR localizes in neurons,
astrocytes, and oligodendrocytes, as well as in microglia
[13,14]. Activation of EGFR was reported to cause for-
mation of cribriform structures in astrocytes, related to
guided migration [15]. EGFR mediates the EGF-induced
chemotactic and chemokinetic migration of microglia
[16], and EGFR signaling functions in several CNS disor-
ders, such as ischemia [17], tuberous sclerosis [18], and
Alzheimer’s disease [19], as well as after SCI [14].
Therefore, we hypothesized that regulation of EGFR
signaling may influence activation of microglia and
associated neuroinflammation, thus attenuating second-
ary damage after SCI. In the present study, lipopolysac-
charide (LPS)-activated microglia cultures and
traumatic SCI rats were used as model systems to ob-
serve phosphorylated EGFR (pEGFR) expression, micro-
glia activation, cytokine production, morphological and
functional outcomes, as well as the underlying mechan-
isms resulting after EGFR blockade by C225 and
AG1478, a blocking antibody and a specific tyrosine
kinase inhibitor, respectively [20,21].
Methods
Detailed information of reagents has been provided in
Additional file 1.
Surgical procedures and reagent delivery
All experimental procedures were performed in accord-
ance with protocols approved by the Governmental Ani-
mal Care Committee of Tongji Medical College. During
surgery, rats were placed on a warming pad to maintain
body temperature of 37.0 ± 0.5°C. After injury, animals
were returned to individual cages with sufficient water
and food; each received a daily penicillin injection
(200,000 U per rat, intramuscular) for three days.
Adult Wistar male rats (240 to 260 g weight) were
randomly assigned into four experimental groups: sham-
operated, SCI-induced, C225-treated, and AG1478-
treated. Traumatic SCI was induced by the weight-drop
technique, as described previously [14]. Briefly, rats were
anesthetized with intraperitoneal ketamine (75 mg/kg)
and xylazine (20 mg/kg) injections. A T11 spinal lamin-
ectomy was made to expose spinal cord, and a moderate
intensity weight drop (10 g × 12.5 cm) was performed by
MASCIS Impactor II (New York University, USA). Rats
in the sham-operated group underwent similar proce-
dures as the SCI-induced group, expect for the weight-
drop step; rats in both groups were treated with saline
through pumps by the following method.
Immediately after SCI induction, a subcutaneous
osmotic pump (Model 2002, Alzet, Cupertino, CA,
USA) was placed closely to the injury site for intrathecal
reagent infusion. Before plantation, the pumps had been
filled with 200 μl saline, C225 (2 μM) or AG1478
(1 mM), connected to a 1.5 mm long PE-10 tube, then
preincubated overnight at 37°C. On day 7 after infusion,
the pump was removed and the wound was closed with
sutures.
Cell culture
Highly purified primary microglia cultures were pre-
pared using modified methods [22]. Briefly, spinal cords
of newborn Wistar pups were dissociated, and cells were
carried in mixed cultures for two days. Medium was
then refreshed with high glucose DMEM containing 20%
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fetal bovine serum. Ten days later, microglia cells were
isolated by an orbital shaker (37°C, 200 rpm, 2 h). Half
an hour after cell implantation, the medium was
refreshed for further purification. After identification
with CD11b antibody, cultures more than 97% pure were
used for experiments.
Since a limited number of primary culture cells are
available, BV2 cells (from the Chinese Academy of Med-
ical Science) were used as succedaneum for western blot
analysis. BV2 is an immortalized microglia cell line that
is reported to share many characteristics with primary
microglia [23,24]. The cells were cultured in fresh high
glucose DMEM supplemented with 10% fetal bovine
serum at a density not exceeding 5 × 105 cells/cm2.
Western blot analysis
After sacrifice under deep anesthesia by transcardial sa-
line infusion, experimental rat spinal cord tissue
(1.5 mm long, centered at the injury site) was quickly
removed and homogenized by sonication in RIPA lysis
buffer. Similarly, cultured cells were lysed by RIPA,
scraped off and collected for protein extraction. Lysates
were centrifuged at 12,000 x g at 4°C for 10 min and
supernatants were collected for the protein concentra-
tion assay, performed using a BCA kit.
Samples containing 60 μg total protein were loaded on
SDS-PAGE (10% for EGFR/pEGFR; 12% for other com-
ponents), and then transferred to nitrocellulose mem-
branes (300 mA, 4 h for EGFR/pEGFR; 250 mA, 2 h for
others). After blocking nonspecific binding, blots were
incubated with primary antibody overnight at 4°C, fol-
lowed by conjugation with horseradish peroxidase
(HRP)-conjugated immunoglobulin G (IgG). Finally,
blots were visualized with enhanced chemiluminescence
(ECL) kits, and resulting digital images were analyzed
by Image J (National Institute of Health, Bethesda, MD,
USA) to obtain the optical densities (OD) of signals.
OD of tested proteins was normalized to OD of β-actin;
the gained ratio was normalized with its corresponding
control (taken as 100%); finally, statistical comparison
was performed and results were expressed as diagrams
(most were shown as Additional file 1).
Cell treatment and experimental tests
Cells were seeded at 1 × 105 cells/cm2 onto glass cover-
slips in 24-well culture plates. Inhibitors were given
30 min before LPS (1 μg/ml) stimulation, with final con-
centrations at 20nM (C225) or 10 μM (AG1478/U0126/
SB203580/SP600125). The solvent served as the control
treatment. Supernatants were collected for ELISA, while
cells were fixed by methanol (−20°C, 15 min) for staining
at various harvesting time points.
Concentrations of IL-1β and TNFα were measured by
ELISA according to the manufacturer’s protocol. For
double-staining, fixed cells were blocked with 5% BSA/
PBS at 20 ± 2°C for 1 h, incubated simultaneously with
CD11b and pEGFR antibody at 4°C for 16 h, incubated
with corresponding fluorescent conjugated anti-IgG at
20 ± 2°C for 1 h, then labeled with DAPI. Finally, the
coverslips were examined at multiple sites under a laser
scanning confocal microscope (LSM710, Carl Zeiss,
Germany). To evaluate cell hypertrophy, somata size of
microglias was semi-quantified according to reported
method [25]. Briefly, Image J software was used to cal-
culate surface areas of CD11b+ cells. At least 20 cells
were randomly collected in each sample, and the
averaged area was taken for statistical analysis.
For reverse transcriptase-PCR, cells were cultured in
12-well plates and the total mRNA was extracted using
MagExtractor (Toyobo, Osaka, Japan). One ug mRNA
was reverse transcribed with ReverTra Ace (Toyobo,
Osaka, Japan). Subsequent PCR reactions were per-
formed with the hot-start PCR mix with a 25 μl reaction
volume, taking 1 μl cDNA as a template. Detailed PCR
procedure has been provided in Additional file 1. After
electrophoresis, images were processed using a Gene
Genius Bio-Imaging system (Syngene, Frederick, MD,
USA). Target gene expression was normalized versus the
housekeeping gene glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) using OD ratios; then, normalized with
its corresponding control (taken as 100%); finally, statis-
tical comparison was performed and results were
expressed as Additional file 1.
Tissue processing, staining and edema analysis
Anesthetized rats were transcardially infused with saline,
followed by ice-cold Zamboni’s fixative. Spinal cord tis-
sues containing the injury site were extracted, fixed for
24 h in Zamboni’s fixative, cryoprotected in 30% sucrose/
0.1 M PBS for three days at 4°C, and finally cut longitu-
dinally into 30 μm sections for fluorescent staining.
Briefly, sections were incubated with primary antibody
for 16 h at 4°C, conjugated with corresponding second-
ary antibody for 1 h at 20 ± 2°C, then observed under a
microscope (Carl Zeiss). Four sections taken at 0.5 mm
intervals in the spinal cord were stained, four fields at
pertinent sites were captured.
Spinal cord edema was evaluated by determining the
water content [26]. After sacrifice, spinal cord tissue
(1.5 mm long, centered at the injury site) was quickly
removed and weighed precisely (wet weight). Then the
tissue was dried for 48 h at 80°C to determinate the dry
weight. Water content = (wet weight− dry weight)/wet
weight × 100%.
Anterograde tracing and behavioral measurement
According to a method described previously [27], 10%
biotinylated dextran amine (BDA) was injected into the
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right side of the spinal cord through the T7-T8 interver-
tebral space 28 d post-SCI. A total of 1 μl BDA was
injected by micropipette with a 0.2 mm diameter tip, at
depths of 0.5 and 1.0 mm, 1.0 mm lateral to the dorsal
median sulcus; four days later, rats were anesthetized
and fixed with Zamboni’s fixative, as described above.
Horizontal 30 μm sections were incubated with fluor-
escein isothiocyanate (FITC)-avidin, followed by glial
fibrillary acidic protein (GFAP) visualization with pri-
mary antibody and cyanine 3 (Cy3)-conjugated IgG.
Labeled tissues were captured under a 10× objective,
and photos were reorganized using Photoshop CS 8.0
(Adobe System Incorporated, San Jose, CA, USA).
Behavioral outcome was evaluated strictly according to
two scales, Basso, Beattie and Bresnahan (BBB) [28] and
combined behavior score (CBS) [29], at days 1, 7, 14 and
28 after SCI, by two trained investigators blinded to the
experimental groups.
Statistical analysis
After a simple randomization, seven rats in each group
were used for behavioral observation, while for other
protocols five samples were used. All the descriptions
about significant difference are based on statistic ana-
lysis, while figures for statistic comparison are added as
supplementary materials. Statistical difference between
groups (defined as P< 0.05) was evaluated with one-way
ANOVA followed by Tukey’s post hoc test. Data are pre-
sented as mean± SE.
Results
EGFR blockade inhibits LPS-induced microglia activation
and EGFR phosphorylation
It was reported that activated primary microglia are
enlarged and have many microspikes covering cell body
surfaces, and display intense immunoreactivity due to
CD11b antigen, as compared to resting microglia with
small, amoeboid shapes [30]. In the present study, such
typical changes have been observed after 3 h LPS stimu-
lation to primary microglia (Figure 1A2). Compared with
control (223.00 cm2 ± 21.95 cm2), a 2.25-fold increase of
cell size in LPS-treated group (502.80 cm2 ± 45.64 cm2)
suggested the hypertrophy of reactive microglias
(Figure 1C). In parallel with morphological activation,
immunoreactivity of pEGFR increased (Figure 1A2),
whereas this was weak in both membrane and cytoplasm
of control cells (Figure 1A1). Similarly, in BV2 cells, re-
active changes and elevated pEGFR expression were
reflected by fluorescent staining (Figure 1B2), while
enhanced expression of CD11b and pEGFR was detected
by western blot analysis (Figure 1D).
However, after either C225 or AG1478 pretreatment,
the following were observed: prevention of the LPS-
induced hypertrophy of primary microglia, resulting in
an average cell size of 276.09 ± 25.53 cm2 and
269.25 ± 26.24 cm2, respectively (Figure 1C); inhibition
of EGFR phosphorylation in primary microglias (Figure
1A3 and A4) and BV2 cells (Figure 1B3 and 1B4), con-
firmed by fluorescent staining; and reduced expression
of CD11b and pEGFR in BV2 cells, demonstrated by
western blot analysis (Figure 1D).
EGFR blockade reduces LPS-induced cytokine production
in microglia
Activated microglia produce an array of proinflamma-
tory factors that are key mediators of neuronal in-
flammation, including IL-1β and TNFα [6]. In the
present study, reverse transcriptase-PCR revealed that
microglial mRNA expression was markedly upregu-
lated after 1 h LPS stimulation (Figure 2A). Although
low in control, secretion of IL-1β and TNFα was dra-
matically enhanced by LPS, to dozens of times the level
found in vehicle-treated groups (57.00 ± 9.18 pg/ml for
IL-1β and 59.6 0 ± 11.59 pg/ml for TNFα); a typical re-
sult included peaks of (1074.40 ± 48.76) pg/ml IL-1β
12 h, and (2086.00 ± 155.52) pg/ml TNFα 6 h, after LPS
stimulation (Figure 2 B and C).
Pretreatment with either C225 or AG1478 depressed
this elevation of both mRNA level (Figure 2A) and pro-
tein secretion (Figure 2 B and C). For example, in C225-
treated groups, IL-1β in the supernatant collected after
12 h of LPS stimulation was (454.40 ± 44.02) pg/ml,
while TNFα was (771.60 ± 74.04) pg/ml after 6 h. No sta-
tistically significant difference was found between the
changes induced by C225 and AG1478, suggesting that
equivalence existed.
MAPK mediates the depression of cytokine production
after EGFR blockade
All three major members of the MAPK family - extracel-
lular signal-regulated kinases (Erk), c-jun terminal kinase
(JNK) and p38 - have been reported to be responsible
for cytokine production [12,31,32]. In this study, after
treatment with LPS, temporal activation in BV2 cells of
each MAPK type was detected by western blot. It was
demonstrated that LPS stimulation resulted in a rapid
phosphorylation, within 0.5 h, of Erk, JNK and p38, and
prolonged phosphorylation of Erk and p38, up to 12 h
after stimulation (Figure 3A1, B1-3).
Expression of IL-1β and TNFα was also determined in
BV2 cells. IL-1β was progressively upregulated during
12 h observation after LPS stimulation (Figure 3A1 and
B4). Accompanying the elevation of pro-IL-1β (31 kDa),
the mature secretory form (17.5 kDa) was synchronously
increased. Similarly, both membrane and soluble forms
of TNFα (26 kDa and 17 kDa respectively) were elevated
at 1 h, peaking 3 h after LPS stimulation (Figure 3A1
and B5). The chronological order of these changes
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suggested that MAPK activation and cytokine produc-
tion may be correlated.
In order to confirm this hypothesis, primary microglias
were pretreated with selective inhibitors of the MAPK
pathways (SB203580 for p38, U0126 for Erk and
SP600125 for JNK) 30 min before LPS treatment separ-
ately; all of which resulted in depressed mRNA expres-
sion and secretion of IL-1β/TNFα, to different degrees
(Figure 3C and D). U0126 was most effective, resulting
in 68.7% inhibition of IL-1β, and 75.4% inhibition of
TNFα, secretion.
Considered collectively, these results support the hy-
pothesis that MAPK signaling mediates LPS-induced
production of both IL-1β and TNFα. MAPK is also
known as a major downstream pathway for EGFR
[33,34], thus was also tested it in BV2 cells after
C225 and AG1478 treatment here. Both them
depressed the phosphorylation of MAPK, especially
activation of Erk and p38 (Figure 3A2-3 and B1-3).
Consistently, production of IL-1β and TNFα was sig-
nificantly reduced after C225 and AG1478 treatment
of BV2 cells (Figures 3A2-3 and B4-5).
Figure 1 EGFR blockade inhibits LPS-induced microglia activation and EGFR phosphorylation. Plated cells were treated with 20nM C225 or
10 μM AG1478 30 min before 1 μg/ml LPS stimulation. After 3 h LPS stimulation, co-staining of CD11b (Green), pEGFR (Red) and nucleus (Blue)
was performed. pEGFR expressed in microglias (A1) and BV2 cells (B1) is elevated after LPS stimulation (A2/B2); C225 (A3/B3) or AG1478
(A4/B4) inhibits LPS-induced overexpression of pEGFR. Scale bar = 50 μm. (C) Comparison of cell size suggests that the microglial
hypertrophy led by LPS is reduced by C225 or AG1478. *P< 0.01 versus sham; #P< 0.01 versus LPS-treated. (D) Western blot analysis of BV2
cells reveals that the LPS-induced upregulation of CD11b and pEGFR is effectively reduced by C225 or AG1478. n = 5. LPS, lipopolysaccharide;
pEGFR, phosphorylated epidermal growth factor receptor.
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EGFR activation appears in reactive microglia in the early
phase following SCI
Although limited expression appeared in spinal cords of
sham-operated rats, pEGFR was immediately induced
and positively expressed on days 1 to 14 after SCI, peak-
ing on day 1, as demonstrated by western blot. Con-
versely, total EGFR experienced a limited change after
the injury (Figure 4A).
EGFR has been reported to be widely expressed in
CNS [13,14]. The current study demonstrated that the
EGFR phosphorylation is positively related to microglial
activation. By double staining, on day 3 after SCI,
CD11b+ microglias surrounding the cavity or in the
boundary zone had reactive morphology and elevated
CD11b immunoreactivity, where high expression of
membrane pEGFR was located (Figure 4C and D). In
contrast, no pEGFR expression was found in resting
microglia from remote areas (Figure 4E).
EGFR blockade reduces EGFR/MAPK activation and
cytokine production after SCI
Continual infusion of either C225 or AG1478 was per-
formed on rats immediately after SCI. To confirm their
pharmacological effects in vivo, pEGFR expression was
examined, and was found to be effectively depressed by
the treatments on day 1 after SCI (Figure 5A). In
addition, although significantly upregulated by SCI,
phosphorylation of Erk and p38 was depressed on day 1
(Figure 5A), while expression of IL-1β and TNFα was
reduced on day 3, after SCI (Figure 5B), by either C225
or AG1478 treatment.
EGFR blockade attenuates secondary damage and
contributes to recovery after SCI
Elevated expression of IL-1β and TNFα was reported to
be essential for glial activation and tissue edema [35,36].
In the present study, microglia and astrocyte activation
was reflected by elevated expression of CD11b and
GFAP on day 7 after SCI (Figure 6A2, B2 and C). Con-
sidered together with results of fluorescent staining and
western blot analysis, the SCI-induced overexpression of
CD11b and GFAP was shown to be attenuated by C225
and AG1478 treatment.
The tissue edema was reflected by water content
comparison (Figure 6D). On day 3 after SCI, increased
water content was revealed in the SCI group
(71.95 ± 0.85%) compared to the sham-operated group
(67.60 ± 0.16%); however, this was significantly reduced
by either C225 or AG1478 pretreatment (69.45 ± 0.51%
and 69.23 ± 0.28%, respectively).
Approximately one month after SCI, anterograde tracing
and GFAP staining were applied together to show mor-
phological recovery of damaged rats. As a result, many
integrated BDA-labeled fibers and terminals were visua-
lized in sham-operated rats (Figure 7A1); however, few
were observed beside or in the caudal side of the injury,
and ongoing degeneration was indicated since most axonal
end bulbs had formed rostral to the lesion in SCI rats
(Figure 7A2). In C225- and AG1478-treated groups, some
thin sprouts extended into the nearby gray matter and
even appeared caudal to the lesion, although these fibers
were shorter in length and branches were fewer in density
than those in the sham group (Figure 7A3 and A4).
Figure 2 EGFR blockade depresses LPS-induced cytokine production in microglia. Purified microglia was treated with 20nM C225 or 10 μM
AG1478 30 min before 1 μg/ml LPS stimulation. (A) Reverse transcriptase-PCR (cells) and (B) ELISA (supernatants) at various time-points. It
demonstrates that C225 and AG1478 depress LPS-induced synthesis/secretion of IL-1β and TNFα. n = 5. *P< 0.01 versus LPS-treated. EGFR,
epidermal growth factor receptor; LPS, lipopolysaccharide.
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Figure 3 MAPK signaling mediates the depression of cytokine production by EGFR blockade. After treated with 20nM C225 or 10 μM
AG1478 30 min before 1 μg/ml LPS stimulation, western blot analysis of BV2 cells was performed to show phosphorylation of the MAPKs (Erk,
JNK and p38) and cytokine production (IL-1β and TNFα). (A) representative photos. (B) Statistical comparison after normalization to β-actin and its
corresponding control. Primary microglia was pretreated with 10 μM selective MAPK inhibitors (SB203580 for p38, U0126 for Erk and SP600125 for
JNK) 30 min before LPS stimulation. Synthesis and secretion of cytokines were tested at 3 h and 6 h after LPS stimulation, respectively. (C) and (D)
show the representative mRNA expression and analyzed supernatant protein concentrations of IL-1β and TNFα, respectively. n = 5. *P< 0.01
versus LPS-treated. EGFR, epidermal growth factor receptor; Erk, extracellular signal-regulated kinases; JNK, c-jun terminal kinase; LPS,
lipopolysaccharide; MAPK, mitogen-activated protein kinases.
Qu et al. Journal of Neuroinflammation 2012, 9:178 Page 7 of 14
http://www.jneuroinflammation.com/content/9/1/178
Reactive astrocytes are the main cell type contributing
to the formation of glial scars [37]. In the present study,
intense GFAP immunoreactivity was detected around
experimental lesions; this was depressed in the C225-
and AG1478-treated groups. Cavity formation is consid-
ered an important characteristic of SCI damage [1]: in
the current study these appeared smaller in the C225-
and AG1478-treated groups than in the vehicle-treated
group.
Aside from the morphological observations, evaluation
of functional recovery was ascertained (Figure 7B), dem-
onstrating the following: that all rats had severe and uni-
form functional deficits 1 d after SCI; behavioral
improvement was observed, but was still incomplete one
month after SCI; and, C225 and AG1478 treatment pro-
gressively mitigated the functional deficits, with statis-
tical differences seven days after treatment, compared to
those in sham-operated rats.
Discussion
The data presented here provide new insights into
the unusual role in microglia activation played by
EGFR signaling. This study has demonstrated the fol-
lowing: microglia activation is accompanied by EGFR
Figure 4 EGFR phosphorylation is elevated in parallel with microglia activation in early-phase SCI. (A) Representative western blots reveal
the elevated expression of pEGFR on days 1 to 14, peaking on day 1. (B) Fluorescent staining of CD11b (Green) demonstrates the gradient
activation of microglias on day 3 after SCI. Bar = 500 μm. Double staining of pEGFR (Red) and CD11b reveals that pEGFR+ reactive microglias
surround the cavity (C) and appear in the boundary zone (D), but not in other areas (E). Bar = 100 μm. Arrow, representative pEGFR+ reactive cells.
pEGFR, phosphorylated epidermal growth factor receptor; SCI, spinal cord injury.
Figure 5 EGFR blockade reduces EGFR/MAPK activation and
cytokine production in vivo. Continual infusion of C225 or AG1478
was performed immediately after SCI (n = 5). Representative photos
of western blots reveal (A) reduced phosphorylated forms of EGFR,
Erk, and p38 on day 1, as well as (B) subsequent downregulated
expression of IL-1β and TNFα on day 3, after C225 or AG1478
treatment. EGFR, epidermal growth factor receptor; Erk, extracellular
signal-regulated kinases; MAPK, mitogen-activated protein kinases.
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phosphorylation both in vitro and in vivo; EGFR blockade
by C225 and AG1478 reduces cytokine production in
microglia through inhibiting the EGFR/MAPK cascade;
and that by modulating the inflammatory response after
SCI, inhibition of EGFR signaling reduces activation of
microglia and astrocytes, attenuates tissue edema, and fi-
nally improves morphological and functional recovery of
SCI rats.
As shown in the present study, round or amoeboid-
shaped activated microglia form a distinct narrow belt
around the lesion by day 7 after SCI. Following SCI,
the normally quiescent microglia are inevitably acti-
vated, with changes in morphology, motility, prolifera-
tion, expression of specific cell surface molecules, and
release of cytokines and chemokines, finally becoming
so-called ‘reactive microglia’ [38]. Reactive microglia
have been considered to be at the center of the injury
cascade [4]. Through releasing molecules such as
TNFα, IL-1, reactive free radicals and nitric oxide,
microglia aggravate early post-injury necrotic cell death,
remote cell apoptosis, tissue edema and axonal degen-
eration [6,39,40].
Therefore, we are persistently trying to modulate
microglia activation to improve recovery after SCI. In
primary microglia cultures, cell motility, one characteris-
tic of microglia activation, has been reported to be mark-
edly enhanced after EGFR activation [16], which
suggests that EGFR is potentially a valuable therapeutic
target. In vitro and in vivo, this study found that acti-
vated microglia highly expressed pEGFR, and blocking
EGFR activation led to decreased microglia activation
and production of IL-1β and TNFα.
Synthesized as a 31 kDa precursor, IL-1β is cleaved to
a 17.5 kDa mature form to gain activity; while TNFα is
initially expressed as a 26 kDa transmembrane protein,
but cleavages to a 17 kDa soluble protein for release.
Previous studies have demonstrated the following: IL-1β
and TNFα are important proinflammatory factors that
mediate changes after SCI [41,42]; infusion of IL-1β into
the spinal cord impairs locomotion [43]; and in the acute
phase of SCI, TNFα transgenic rats have more spinal
cord apoptotic cells than do wild-type rats [41]. What is
more, accumulating evidence suggests that moderating
production of these factors in early-phase SCI can
Figure 6 EGFR blockade attenuates cell activation and tissue edema after SCI. Fluorescent staining reveals (A2 and B2) the activation of
microglia and astrocytes on day 7 after SCI, which was attenuated by (A3 and B3) C225 and (A4 and B4) AG1478 treatments. Bar = 200 μM. (C)
Similar findings by western blot analysis of CD11b and GFAP 7 day after SCI. (D) Water content of spinal cord reveals that SCI-induced edema
was reduced by three days C225/AG1478 treatment. n = 5. #P< 0.01 versus sham; *P< 0.01 versus SCI. EGFR, epidermal growth factor receptor;
GFAP, glial fibrillary acidic protein; SCI, spinal cord injury.
Qu et al. Journal of Neuroinflammation 2012, 9:178 Page 9 of 14
http://www.jneuroinflammation.com/content/9/1/178
benefit recovery. For example, blocking IL-1β with re-
ceptor antagonists was shown to be useful for counter-
acting glutamate toxicity and improved morphological
and functional recovery [43,44], and inhibition of
TNFα either by reagents or antagonist significantly
reduced development of inflammation, suppressed neur-
onal and oligodendroglial apoptosis, facilitated myelin re-
generation and improved functional recovery after SCI
[45-47].
This study demonstrates that inhibition of EGFR phos-
phorylation reduces production of IL-1β and TNFα by
activated microglia. However, the mechanisms under-
lying this change remain unclear. Previous reports sug-
gest MAPK signaling pathways might be involved, as
follows: 1) the key downstream pathway for LPS-
induced signaling events is the MAPK cascade [11]; 2)
activation of MAPK was observed to initiate inflamma-
tory responses and aggravated degeneration of neurons
in SCI models [48,49]; 3) MAPK is one of the three
major downstream pathways for EGFR regulation
[33,34]. The present study showed that MAPK was acti-
vated by LPS; MAPK inhibitors reduced production of
IL-1β and TNFα; in addition, C225 and AG1478
depressed activation of Erk and p38, as well as the ex-
pression of IL-1β and TNFα. Considered together, these
results suggest that EGFR inhibitors depress inflamma-
tion after LPS stimulation and SCI, through regulating
the activation of EGFR/MAPK cascade in microglia,
Figure 7 EGFR blockade promotes morphological and functional recovery. (A2) Combining GFAP staining (red) with BDA tracing (green),
fluorescent staining of spinal cord reveals glial scar and cavity formation, as well as limited axonal regeneration after SCI; (A3 and A4)
amelioration observed after C225 and AG1478 treatment. Bar = 1 mm. (B) Temporal changes in behavioral outcomes, as evaluated by BBB (B1)
and CBS (B2) scoring, indicate that C225 and AG1478 improved functional recovery beginning on day 7 after SCI. n = 7. *P< 0.05 versus SCI. BBB,
Basso Beattie and Bresnahan; BDA, biotinylated dextran amine; CBS, combined behavior score; EGFR, epidermal growth factor receptor; GFAP, glial
fibrillary acidic protein; SCI, spinal cord injury.
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which may be a new neuroprotective mechanism after
EGFR blockade.
MAPKs are important for intracellular signal trans-
duction and play critical roles in regulating cell prolif-
eration, neural plasticity, inflammatory responses and
other biological activities. Previous reports reviewed that
p38 and p44/42 MAPKs may play a critical role in
harmful microglial activation in acute brain injury [50];
JNK is activated by proinflammatory cytokines and cel-
lular stress, and play essential roles in regulating inflam-
matory responses [51,52]; activation of MAPK entities,
especially Erk and p38, is a determinant of neuronal
survival on certain occasions [53-55]; and, selective inhi-
bitors (PD98059 and SB203580) are candidates for treat-
ment [48,49]. We here found that reducing the
activation of each MAPK led to the suppression of cyto-
kine production at a different degree, supported by pre-
vious reports [32,56]; however, further study is needed
to understand the variability between each MAPK
signaling.
Secondary damage after SCI is a complicate cascade
that involves several immune cell types, including micro-
glia and astrocyte. According to previous reports, activa-
tion of microglia is always initialed by proinflammatory
factors, and contributes to activation of astrocytes
[36,57-59]. We conclude that EGFR blockade may de-
press cell activation through modulating inflammation,
although other mechanisms are possibly operational. For
example, astrocytes can be directly activated by EGF
through the Rheb-mTOR pathway [60], and the chemo-
tactic migration of microglia was reported to be induced
by EGF [16].
Similar to cell activation, the occurrence of tissue
edema is a multifactorial process that must include an
inflammatory response and disruption of ion regulation
and cellular metabolism [35,61]. In the present study,
depressed inflammation and cell activation may have
ameliorated the altered cellular metabolism and water
infiltration after SCI, finally contributing to reduced tis-
sue edema after treatment.
Secondary insults, especially microglia-mediated in-
flammatory responses and reactive astrogliosis, result in
the formation of glial scars and cavities, which have
been described as molecular and physical barriers to
axonal outgrowth [62]. In contrast to the increased
numbers of GFAP-positive astrocytes, large cavity for-
mation and severe axonal damage that appear a month
after SCI, in the present study reduced astrogliosis and
cavitation, improved axonal growth and functional re-
covery were observed in the C225- and AG1478-treated
groups. It is well known that functional recovery
depends on the extent of spared fiber tracts,
reorganization of segmental circuitry, and restoration of
supraspinal input. Therefore, we presume that through
attenuating secondary damage, EGFR blockade provides
a beneficial microenvironment for axonal growth, which
underlies the subsequent functional improvement. Be-
sides, the wide distribution and multiple functions of
EGFR suggest that other mechanisms might underlie
the improvement also, for example, regulation of vessel
permeability, attenuation of astrogliosis-associated in-
juries and blockade of the activities of myelin inhibitors
[14,63-65].
It is improper to view microglia activation and inflam-
matory responses as absolutely damaging or beneficial
after CNS trauma. Rather the timing for modulation
must be considered. Since previous reports suggest that
early-phase inflammation is detrimental [5,39,41], we
assessed the EGFR regulation in early-phase SCI. Further
investigation is needed in order to find the best treat-
ment protocol.
SCI is a catastrophe comprising multiple events. Limi-
tation of methods adopted here results in some impre-
cise information from animal research, although it can
elucidate the observed pathological phenomena more or
less. As a newly recognized therapeutic target, regulating
EGFR signaling is thought to be neuroprotective. How-
ever, negative evidence also exists; for example, EGF was
reported to exert a neuroprotective role for the brain
after injury [66], and AG1478 promotes CNS axonal
growth through certain EGFR-independent processes
[67]. Actually, many studies have shown that EGFR can
play roles beyond the usual ligand-dependent one, espe-
cially after CNS disorders. For example, EGFR can be
transactivated after the activation of other membrane
receptors, such as angiotensin II receptors [68] and β-2
adrenergic receptors [69]; unpublished results from our
group reveal that LPS stimulates phosphorylation of
EGFR through enhancing endocelluar calcium activity.
Rapid activation of EGFR signaling also occurs after sev-
eral other CNS disorders, such as electrolytic lesions
and entorhinal ablation [70,71], in the damaged brains
of patients after stroke, and in those with Alzheimer’s
disease [19,72]. Thus, there is a need for further studies
into the intricate regulation of EGFR, especially after
CNS injury.
Conclusion
In summary, we report that EGFR signaling is essential
for microglia activation and cytokine production, making
it a potential therapeutic target for treatment of CNS in-
flammatory diseases. Rats subjected to spinal cord
trauma can be effectively treated with the potent EGFR
blockers C225 and AG1478, through modulation of neu-
roinflammation and associated secondary damage. The
fact that EGFR blockers are already used in preclinical
research or in clinical settings makes them particularly
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attractive candidates for clinical trials of SCI treatment
modalities.
Additional file
Additional file 1: Table S1. Detailed information of reagents used in
the present study. Table 2: Detailed PCR procedure used in the present
study. Figure S1: Statistic comparison of CD11b and pEGFR expression in
BV2 cells (corresponding to figure 1D). Control was taken as 100%. OD of
tested proteins was normalized to OD of β-actin and its corresponding
control. n = 5. #, P< 0.01, versus control; *, P< 0.01, versus LPS-treated
group. It demonstrates that LPS-induced elevation of CD11b (A), pEGFR
(B), EGFR (C) and pEGFR/EGFR ratio (D), all of which were downregulated
by C225 or AG1478 equivalently. Figure S2: Statistic comparison of
mRNA expression (corresponding to figure 2A). Control was taken as
100%. Target gene expression was normalized versus GAPDH and its
corresponding control. n = 5. *, P< 0.05, versus LPS-treated group. It
demonstrates that LPS induced a rapid but persistent elevation of IL-1β
(A) and TNFα (B) mRNA expression in primary microglias, which can be
reduced by pretreatment of C225 or AG1478. Figure 3: Statistic
comparison of mRNA expression (corresponding to figure 3C/D). Control
was taken as 100%. Target gene expression was normalized versus
GAPDH and its corresponding control. n = 5. #, P< 0.05, versus control. *,
P< 0.05, versus LPS-treated group. Primary microglias were treated by
selective inhibitors of the MAPK pathway (SB203580 for p38, U0126 for
Erk1/2 and SP600125 for JNK) 30 min before LPS treatment separately,
each was found to reduce the LPS-induced mRNA expression of IL-1β
and TNFα at 3 h after LPS stimulation, to different degrees. Figure 4:
Semi-quantitative comparison of protein expression after SCI
(corresponding to figure 4A). Sham was taken as 100%. OD of tested
proteins was normalized to OD of β-actin and its corresponding control.
n = 5. *, P< 0.05, versus sham. Time-dependent analysis demonstrates
that expression of pEGFR is upregulated during 0.25 d and 14 d after SCI,
with peak at 1 d after SCI; expression of EGFR is reduced at 1 d after SCI,
however, upregulated at 3 d and 7 d; and, the pEGFR/EGFR ratio is
elevated during 0.25 d and 7 d after SCI, with peak at 1 d after SCI.
Figure 5: Semi-quantitative comparison of protein expression after
treatment to SCI rats (corresponding to figure 5). Sham was taken as
100%. OD of tested proteins was normalized to OD of β-actin and its
corresponding control. n = 5. #, P< 0.05, versus sham; *, P< 0.05, versus
SCI. It demonstrates that SCI induces overexpression of pEGFR/p-Erk/p-
JNK/p-p38 (1 d after SCI, A-D) and IL-1β/ TNFα (3 d after SCI, E/F);
except JNK, all others can be partly attenuated by either C225 or
AG1478. Figure 6: Semi-quantitative comparison of protein expression
(corresponding to figure 6C). Fluorescent staining was performed on SCI
tissues, followed by IOD analysis with Image J, which (A and B)
demonstrates that SCI induced fierce elevation of CD11b and GFAP
expression, the markers for microglia and astrocyte respectively, at day 7
after SCI; all of which are reduced by 7 d treatment with either C225 or
AG1478. Those findings have been supported by western blot analysis,
provided in C1 and C2. n = 5. #, P< 0.05, versus sham; *, P< 0.05, versus
SCI. (DOC 409 kb)
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